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Objective: The application of thoracic endovascular aortic repair (TEVAR) has changed treatment paradigms for thoracic
aortic disease. We sought to better deﬁne speciﬁc treatment patterns and outcomes for type B aortic dissection treated
with TEVAR or open surgical repair (OSR).
Methods: Medicare patients undergoing type B thoracic aortic dissection repair (2000-2010) were identiﬁed by use of a
validated International Classiﬁcation of Diseases, Ninth Revision diagnostic and procedural codeebased algorithm.
Trends in utilization were analyzed by procedure type (OSR vs TEVAR), and patterns in patient characteristics and
outcomes were examined.
Results: Total thoracic aortic dissection repairs increased by 21% between 2000 and 2010 (2.5 to 3 per 100,000
Medicare patients; P [ .001). A concomitant increase in TEVAR was seen during the same interval (0.03 to 0.8 per
100,000; P < .001). By 2010, TEVAR represented 27% of all repairs. TEVAR patients had higher rates of comorbid
congestive heart failure (12% vs 9%; P < .001), chronic obstructive pulmonary disease (17% vs 10%; P < .001), diabetes
(8% vs 5%; P < .001), and chronic renal failure (8% vs 3%; P < .001) compared with OSR patients. For all repairs, patient
comorbidity burden increased over time (mean Charlson comorbidity score of 0.79 in 2000, 1.10 in 2010; P [ .04).
During this same interval, in-hospital mortality rates declined from 47% to 23% (P < .001), a trend seen in both TEVAR
and OSR patients. Whereas in-hospital mortality rates and 3-year survival were similar between patients selected for
TEVAR and OSR, there was a trend toward women having slightly lower 3-year survival after TEVAR (60% women vs
63% men; P [ .07).
Conclusions: Surgical treatment of type B aortic dissection has increased over time, reﬂecting an increase in the utilization
of TEVAR. Overall, type B dissection repairs are currently performed at lower mortality risk in patients with more
comorbidities. (J Vasc Surg 2014;60:11-9.)Deﬁnitive management of Stanford type B thoracic
aortic dissection remains a clinical challenge. This challenge
arises from the wide variations in patient presentations and
symptoms encountered in thoracic dissections and differing
provider-speciﬁc thresholds for intervention. In the acute
setting, open surgical repair (OSR) has been the historical
standard of treatment for type B dissection complicated
by organ malperfusion, intractable pain, uncontrollable
hypertension, potential impending rupture, or rapid
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://dx.doi.org/10.1016/j.jvs.2013.12.047undergoing OSR for acute type B dissection are as high
as 29% to 34%.2-4 After the introduction of thoracic endo-
vascular aortic repair (TEVAR), endovascular techniques
have been incorporated into treatment paradigms for
acute, complicated type B dissection to prevent rupture
or end-organ damage.1,5-7 Furthermore, TEVAR has
recently been used in the setting of chronic type B dissec-
tion to prevent and to treat aneurysmal degeneration,8-10
thus potentially expanding the patient population consid-
ered for intervention.
The introduction of TEVAR has led to an increasing
rate of overall repairs in patients with thoracic and thora-
coabdominal aortic aneurysms.11 However, it remains
unclear how endovascular stent grafting has affected prac-
tice patterns for the treatment of type B dissection.
Reports on patient characteristics and outcomes after
repair of type B dissection largely remain limited to
single-center series and registries.3,6,7 Results from two
large population-based cohorts have been reported, but
these reﬂected relatively short time intervals, spanning
3 years or less.12,13
Therefore, we sought to examine how TEVAR has
changed the trends and outcomes in repair of type B dissec-
tion across the United States. We studied all patients un-
dergoing repair of type B dissection in the U.S. Medicare
population during a 10-year period, examining trends in11
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and outcomes.
METHODS
Database and cohort assembly. The database used
for this analysis was the Medicare Physician/Supplier File
and the Medicare Denominator File for the years 2000
to 2010. First, all patients with a diagnosis of thoracic
aortic dissection were identiﬁed by the International Clas-
siﬁcation of Diseases, Ninth Revision (ICD-9) diagnosis
codes 441.0, 441.01, and 441.03. Next, ICD-9 proce-
dure codes were used to identify all patients with a diag-
nosis of thoracic aortic dissection who underwent either
OSR (38.35 and 38.45) or TEVAR (39.79 and 39.73;
Supplementary Table, online only).
All patients with a concomitant diagnosis of thoracic
aortic aneurysm were excluded as many of these were likely
to represent patients treated for chronic dissection with
aneurysmal degeneration. In addition, to remove Stanford
type A dissections from the database, patients with
concomitant procedure codes for valve replacement, coro-
nary artery bypass graft, aortic arch replacement, or cardio-
pulmonary bypass with circulatory arrest were also
excluded. Similar analytic algorithms have been previously
used and validated to select type B dissections from admin-
istrative databases.12-14 Claims not included in the Medi-
care Denominator File were also excluded.
Patients were required to have at least 12 months of
Medicare eligibility before surgery. Because Medicare is
available only to patients once they are 65 years old, we
excluded patients younger than 66 years old as this meant
that they would not yet have received Medicare for a full
12 months. During the 12-month lead-in period, ICD-9
codes from 19 categories of patient comorbidities were
used to construct patient-speciﬁc Charlson scores.14,15
The Charlson score is a comorbidity score that has been
validated for use with administrative data sets and reﬂects
the comorbidity proﬁle of patients based on the ICD-9
codes their ﬁle contains.
Trends and outcomes. Changes in practice patterns
for the treatment of type B dissection were analyzed in
two ways. First, the numbers of TEVAR, OSR, and total
repairs were analyzed on an annual basis with use of the
total Medicare population as the denominator to deter-
mine rates of repair that were comparable across years.
Next, the proportions of TEVAR and OSR per year
were studied with total repairs as the denominator to
determine the impact of each technique on total repairs
annually.
Patient characteristics were analyzed among those
undergoing TEVAR and OSR using data elements present
in the Medicare database with speciﬁc attention to deﬁned
Charlson comorbidity categories. Our main outcome mea-
sures were in-hospital morbidity, perioperative mortality,
and long-term mortality, determined at 3 years of follow-
up. Although postoperative paraparesis and paraplegia are
complications of interest in patients undergoing type B
dissection repair, these are not coded reliably in theMedicare database and therefore could not be studied as
an outcome.
Statistical analysis. Patient demographics were
compared between groups by a Wilcoxon rank sum test
for continuous variables and c2 test for categorical or
dichotomous variables. Trends in procedure rates over
time were compared by the Spearman test, whereas a
nonparametric test for trend across ordered groups was
used in comparing trends in patient comorbidities and peri-
operative mortality. In-hospital morbidity and periopera-
tive mortality were binary categorical variables and were
analyzed with c2 tests.
Survival at 3 years was established with the Medicare
Denominator File using speciﬁed date of death. Survival
curves were estimated by Kaplan-Meier analysis, and life-
table analysis was used to establish rates of survival at 3 years
with surrounding 95% conﬁdence intervals (CIs). Log-rank
tests were used to determine signiﬁcant differences in sur-
vival between groups. P values < .05 were considered sta-
tistically signiﬁcant. Data were analyzed with use of Stata
version 11 (StataCorp, College Station, Tex).
RESULTS
Changes in use of OSR and TEVAR over time.
Between 2000 and 2010, the overall rate of repair of type B
dissection increased by 21%, from 2.5 to 3.0 per 100,000
Medicare beneﬁciaries (P ¼ .001; Fig 1). Concurrently,
there was a decrease in the rate of OSR from 2.5 to 2.2 per
100,000 beneﬁciaries (P ¼ .007) and a marked increase in
the rate of TEVAR from 0 to 0.8 per 100,000 beneﬁciaries
(P < .001). The most notable increase in TEVAR occurred
after 2005 with the introduction of the TEVAR-speciﬁc
ICD-9 procedural code (39.73; Supplementary Table,
online only).
We next examined trends in procedure type by deter-
mining the proportion of all procedures that were
TEVAR vs OSR on an annual basis. In 2000, OSR rep-
resented 99% of all type B dissection repairs, whereas
TEVAR represented 1% (Fig 2). During the 10-year
study period, TEVAR became more frequently performed
such that by 2010, 27% of all type B dissection repairs
were endovascular based, and the proportion of OSR
had decreased to 73%.
Patient characteristics and Charlson comorbidity
proﬁles. Between 2000 and 2010, 11,159 patients under-
went repair of type B dissection. Of these, 9470 patients
underwent OSR (85%) and 1689 underwent TEVAR
(15%) (Table). Patients undergoing TEVAR were older
(75.8 years TEVAR, 74.5 years OSR; P < .001) and were
less likely to be male (54% TEVAR, 56% OSR; P ¼ .04) or
white (82% TEVAR, 89% OSR; P < .001).
TEVAR patients were also more likely to have a num-
ber of comorbid conditions. TEVAR patients had
increased rates of prior myocardial infarction (6% vs 5%;
P ¼ .02), congestive heart failure (12% vs 9%; P < .001),
peripheral vascular disease (34% vs 15%; P < .001), cere-
brovascular disease (5% vs 3%; P ¼ .001), chronic pulmo-
nary disease (17% vs 10%; P < .001), dementia (1% vs
Fig 2. Proportion of open surgical repair (OSR) vs thoracic endovascular aortic repair (TEVAR) in Medicare patients
undergoing type B dissection repair, 2000-2010.
Fig 1. Rates of type B aortic dissection repair in Medicare patients, 2000-2010, stratiﬁed by procedure type. CI,
Conﬁdence interval; TEVAR, thoracic endovascular aortic repair.
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renal failure (8% vs 3%; P < .001), and cancer (4% vs 3%;
P ¼ .02; Table). The mean Charlson score among TEVAR
patients was 1.6 (95% CI, 1.5-1.7), signiﬁcantly higher
than the score of 0.9 (95% CI, 0.8-0.9) in the OSR group,
representing an overall higher comorbidity burden in the
endovascular group (P < .001).
To determine how the comorbidity proﬁle of patients
undergoing repair has changed over time, the mean Charl-
son score was determined for each group in 2-year incre-
ments. The mean Charlson score for overall repairs was0.79 at the beginning of the study period (2000-2001)
and increased to 1.10 by 2010 (P ¼ .04; Fig 3). When
stratiﬁed by procedure type, OSR patients had a mean
Charlson score of approximately 0.8 throughout the study
period. By comparison, patients undergoing TEVAR had
uniformly increased mean Charlson scores compared with
OSR patients (Fig 3).
In-hospital outcomes and perioperative mortality
trends in TEVAR and OSR. When in-hospital outcomes
were analyzed, OSR was associated with higher rates of
perioperative stroke (13% vs 9%; P < .001), renal
Table. Demographics, comorbidities, and in-hospital complications for Medicare patients who underwent repair of type
B thoracic aortic dissection, 2000-2010, with univariate analysis by open surgical repair (OSR) vs thoracic endovascular
aortic repair (TEVAR)
Variable OSR TEVAR P valuea
Number of patients 9470 1689
Age, yearsb 74.5 (74.4-74.6) 75.8 (75.5-76.1) <.001
Male 5340 (56) 906 (54) .04
White 8381 (89) 1391 (82) <.001
Charlson categories
History of myocardial infarction 481 (5) 109 (6) .02
Congestive heart failure 860 (9) 207 (12) <.001
Peripheral vascular disease 1450 (15) 573 (34) <.001
Cerebrovascular disease 288 (3) 78 (5) .001
Chronic pulmonary disease 927 (10) 285 (17) <.001
Dementia 36 (0.4) 16 (1) .002
Peptic ulcer disease 96 (1) 23 (1) .2
Diabetes 456 (5) 140 (8) <.001
Hemiplegia or paraplegia 16 (0.2) 7 (0.4) .04
Chronic renal failure 262 (3) 140 (8) <.001
Cancer 258 (3) 63 (4) .02
Total Charlson score 0.9 (0.8-0.9) 1.6 (1.5-1.7) <.001
In-hospital complications
Death 3757 (40) 448 (27) <.001
Stroke 1189 (13) 152 (9) <.001
Bowel 84 (1) 19 (1) .3
Renal 1549 (16) 209 (12) <.001
Pulmonary 4446 (47) 531 (31) <.001
Length of stay, daysc 15.7 (15.4-16.0) 12.1 (11.5-12.8) <.001
Readmission within 30 days 1833 (19) 349 (21) .2
Readmission length of stay, daysc 7.3 (6.9-7.7) 6.6 (5.9-7.2) .1
CI, Conﬁdence interval.
Continuous data are presented as mean (95% CI) and categorical data as number (%).
aP value from c2 test for dichotomous variables.
bP value from independent group t-test.
cP value from independent group t-test.
Fig 3. Mean Charlson comorbidity score of Medicare patients undergoing type B dissection repair in 2-year
increments, 2000-2010, stratiﬁed by procedure type. TEVAR, Thoracic endovascular aortic repair.
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Fig 4. Rates of perioperative mortality in Medicare patients undergoing type B aortic dissection repair, 2000-2010,
stratiﬁed by procedure type. Thoracic endovascular aortic repair (TEVAR) years 2000 and 2001 are condensed to a
single time point because of low total numbers of TEVAR in those years.
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complications (47% vs 31%; P < .001) compared with
TEVAR (Table). Mean length of stay was shorter in the
TEVAR group at 12.1 days compared with 15.7 days in the
OSR group (P < .001). OSR and TEVAR patients were
equally likely to be readmitted (19% vs 21%; P ¼ .2).
Of the 11,159 patients undergoing repair during the
10-year study period, perioperative death occurred in
4205 (38%). The perioperative mortality rate was 40% in
the OSR group (3757 of 9470) compared with 27% in
the TEVAR group (448 of 1689; P < .001).
However, when we examined trends in perioperative
mortality, there was signiﬁcant improvement in periopera-
tive mortality rates over time (Fig 4). Mortality rates for
overall repairs decreased signiﬁcantly from 47% in 2000
to 23% in 2010 (P < .001). Signiﬁcant decreases were
also seen when annual perioperative mortality rates were
stratiﬁed by procedure type. For OSR, perioperative mor-
tality improved from 47% in 2000 to 25% in 2010 (P <
.001); for TEVAR, perioperative mortality improved
from 47% for the two combined years 2000 and 2001
(when only 58 procedures were performed) to 18% in
2010 (P < .001).
Three-year survival by repair type and gender. Pa-
tients undergoing TEVAR had a 3-year survival rate of
61% (95% CI, 58.5-63.4), which was not signiﬁcantly
different from the open repair 3-year survival rate of 59.0%
(95% CI, 58.0-60.0; P ¼ .16). This was true despite the
fact that TEVAR patients appeared to do better in the
immediate postoperative period on the basis of the Kaplan-
Meier curves (Fig 5).
Because of recent reports of potential gender-related
disparities in survival and anatomic suitability for endovas-
cular repair among patients with aortic dissection16 and
abdominal aortic aneurysms,17,18 we further stratiﬁedsurvival at 3 years by gender and procedure type (Fig 6).
We observed that women and men had similar 3-year sur-
vival after OSR (58.3% [95% CI, 56.8-59.8] in women vs
59.6% [95% CI, 58.2-60.9] in men; P ¼ .29). However,
there was a trend toward inferior 3-year survival among
women undergoing TEVAR (59.3% [95% CI, 55.6-
62.8] in women vs 62.4% [95% CI, 59.0-65.7] in men;
P ¼ .07).
DISCUSSION
The application and evolution of TEVAR have led to
dramatic changes in the treatment of thoracic aortic dis-
ease. Previous studies have shown that TEVAR is now
being applied for a variety of thoracic aortic diseases,12
and in the case of thoracic aortic aneurysm, adoption of
TEVAR has led to an increase in the overall number of re-
pairs performed nationwide.11 Our study demonstrates
that more than one fourth of type B dissection repairs are
now performed in an endovascular fashion and that the
adoption of these techniques has led to an increase in the
rate at which type B dissections are being repaired. Further-
more, patients treated with TEVAR appear to have signif-
icantly more comorbidities than do patients undergoing
open repair. Despite these differences in patient character-
istics, TEVAR patients have lower rates of in-hospital
morbidity and mortality compared with OSR patients and
comparable 3-year survival rates. Thus, TEVAR for type
B dissection has expanded the group of patients being
offered repair to include those with more comorbidities
without incurring inferior outcomes.
Interestingly, we found that the adoption of TEVAR
for type B dissection has coincided with a dramatic decrease
in perioperative mortality rates for all patients undergoing
repair, a phenomenon observed for both TEVAR and
open repair groups. These changes have occurred, we
Fig 5. Kaplan-Meier curves for overall survival in open surgical repair (OSR) vs thoracic endovascular aortic repair
(TEVAR) with life-table analysis showing 3-year survival (inset). P value from log-rank test. Total patients at risk for
various time points are also shown (bottom).
Fig 6. Kaplan-Meier curves for overall survival in men vs women after open surgical repair (OSR; top) and thoracic
endovascular aortic repair (TEVAR; bottom). P value from log-rank test. Three-year survival estimates, from life-table
analysis (right).
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tion and (2) a possible shift in the perceived threshold for
repair of type B dissection. At the beginning of our study
period, in 2000, nearly every patient was being treated
with open repair, which was mostly reserved for patientswith acute type B dissection complicated by impending
rupture, organ malperfusion, intractable pain, uncontrolla-
ble hypertension, or rapid growth.1,19 For patients in
the International Registry of Acute Aortic Dissection
(IRAD), open repair in this setting incurred a perioperative
JOURNAL OF VASCULAR SURGERY
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operative mortality rate, in 2000, of 47% reported here.
During the course of the study period, TEVAR was
adopted, allowing the treatment of more comorbid pa-
tients; and as rates of TEVAR increased, the rates of over-
all repairs performed also increased by 21%. By 2010,
patients who presented with clear-cut indications for
repair of type B dissection could be considered for either
TEVAR or OSR. Patients who may have not previously
been offered open repair could now be treated with
TEVAR. We believe that improved patient selection for
both treatment modalities, based on patient comorbidity
and dissection anatomy, contributed to improvement in
perioperative mortality rates over time. These improve-
ments in perioperative mortality for an acute aortic process
are not without precedent as similar dramatic decreases in
mortality were seen for both intact and ruptured abdom-
inal aortic aneurysms after the introduction of endovascu-
lar aneurysm repair (EVAR).20
Concurrently, some surgeons began advocatingTEVAR
for additional indications: uncomplicated subacute or chr-
onic dissection to prevent future aneurysmal degenera-
tion.1,9,19,21 As a result, it is likely that the acuity of
presentation of type B dissections undergoing repair was
“diluted” over time by selection of patients for repair who
presented with uncomplicated subacute or chronic disease.
This effect has probably also contributed to improvements
in perioperative mortality. Unfortunately, our current data
set does not allow us to determine the extent to which
this has occurred. These efforts will require detailed clinical
registries, such as the Vascular Quality Initiative’s national
TEVARdata set, to examine if differences in patient selection
and disease anatomy are driving the changes we have
observed in our current analysis.
Trends in the adoption of TEVAR described here are
likely to represent only the initial stages of even broader
application of endovascular treatments for type B dissec-
tion. Although more than one fourth of type B dissections
were being repaired by TEVAR in 2010, this proportion is
likely to increase further. Population-based studies have
shown that TEVAR is used for one third of thoracic aortic
aneurysm repairs11 and that EVAR is applied in more than
half of abdominal aortic aneurysm repairs.20,22 Recently,
the U.S. Food and Drug Administration approved the ﬁrst
endovascular device for acute and chronic type B dissec-
tion, a regulatory decision that will surely increase the avail-
ability and promotion of this technology. As a result, it is
likely that more patients with type B dissection will be
treated with TEVAR and that future device improvements
will allow the treatment of more complex anatomic disease.
Prospective, detailed clinical registries will also be essential
in continuing to study the adoption of TEVAR for type B
dissection as it becomes more widely applied.
Our ﬁndings are consistent with others showing that
TEVAR patients tend to have more comorbidities than
do patients undergoing OSR for acute type B dissection.
A study of the Nationwide Inpatient Sample from 2005
to 2007 showed that TEVAR patients had higher ratesof renal failure, hypertension, history of myocardial infarc-
tion, and peripheral vascular disease, whereas rates of
postoperative cardiac complications, respiratory complica-
tions, and acute renal failure were lower compared with
patients undergoing open repair.13 We found that
TEVAR patients were more likely to carry diagnoses of
multiple comorbid diseases compared with OSR patients.
Though useful in representing the overall chronic comor-
bidity burden, it should be stressed that the Charlson
score does not offer a description of the patient’s acute
presentation, such as dissection anatomy, presence of
symptoms, and hemodynamic parameters. The overall in-
crease in Charlson score observed from 2000 to 2010
suggests that patients with more chronic comorbidities
are undergoing repair than previously, implying that the
perception of TEVAR as a less invasive treatment option
has expanded the patients deemed eligible for repair.
The 3-year survival rates reported here for TEVAR
(62%) and OSR (59%) are lower than those recently
reportedby the IRAD(TEVAR,76%;OSR, 83%),6 although
they are consistent with 5-year survival rates reported from
another study using Medicare data spanning a shorter time
(TEVAR, 58%; OSR, 51%).12 These outcomes are likely to
be slightly inferior to those reported in IRAD and random-
ized studies because they represent type B dissections
repaired across multiple institutions, in a real-world setting,
and only patients older than 65 years are included.
Gender also appears to potentially have an impact on
prognosis in aortic dissection. IRAD investigators identi-
ﬁed gender as a risk factor in all thoracic dissections,
showing that surgical outcomes and long-term mortality
were inferior among women compared with men treated
for aortic dissection.6,16 Worse outcomes in women have
also been seen with the use of endovascular techniques
for the treatment of abdominal aortic aneurysm. On the
basis of blinded anatomic analyses, women are less likely
than men to meet device-speciﬁc criteria for EVAR.17
Further, a retrospective review of the EUROSTAR data-
base showed that women undergoing EVAR had higher
complication and reintervention rates than men did.18
Our data imply a trend toward inferior outcomes in women
undergoing endovascular repair of type B dissection
compared with men, whereas no difference was seen in
outcomes for open repair stratiﬁed by gender. These results
suggest a potential impact of gender on surgical outcomes
that justify further study of TEVAR for type B dissection.
Randomized controlled trials evaluating the use of
TEVAR for type B dissection are clearly needed. Long-
term results from the INSTEAD trial and results of the
ADSORB trial23 will help determine the safety and efﬁcacy
of TEVAR in this setting. However, these data will likely be
susceptible to multiple interpretations.24 Our results offer
important insights into how new technology is adopted,
even in the absence of randomized data supporting its
use, and depict how type B dissections are repaired in
more than 10,000 patients in a real-world setting.
Our study has several limitations. First, the data set con-
tains no anatomic data. Although we are conﬁdent that we
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rithm, we cannot determine whether dissections involved
visceral arteries or were associated with intramural hema-
tomas/penetrating ulcers or frank rupture. These are impor-
tant considerations, and changes in type B dissection
anatomy may have occurred during the study period. Sec-
ond, we are unable to determine the timing of intervention
with regard to the onset of symptoms. During the study
period, TEVAR emerged as a potential therapy to prevent
aneurysmal degeneration of chronic dissection.8,9 Although
the validity of this is still being studied, the practice of treat-
ing chronic dissection with TEVAR has presumably been
adopted by some, and it is unclear how this has affected na-
tional practice patterns. Similarly, it is unknown if there have
been any changes in dissection anatomy or timing of inter-
vention in patients undergoing open repair, factors that
may have contributed to improved perioperative mortality
in this group. Third, there is sure to be heterogeneity in
the devices used for TEVAR in this database, although we
do not have any device-speciﬁc information, thus limiting
our ability to determine howdevices are being used. Further-
more, we have no information on chimney techniques, fen-
estrations, and other modalities that may be inﬂuencing the
overall endovascular treatment of type B dissection.
Although our coding strategy has been previously vali-
dated,11,14 there is always the potential for coding errors
and misclassiﬁcations in administrative data sets, and the
extent to which this occurred cannot be known. Specif-
ically, there may be a small number of type A dissection re-
pairs included in this data set if they did not carry
concomitant codes for valve replacement, coronary artery
bypass graft, aortic arch replacement, or cardiopulmonary
bypass with circulatory arrest, although we believe, on
the basis of our prior validation of this algorithm, that
misclassiﬁcation occurs infrequently. Also, the TEVAR-
speciﬁc ICD-9 code (39.73) was only introduced in
2005, midway through the study period. However, we
believe that the pattern of use for the two codes represent-
ing TEVAR (39.73 and 39.79; Supplementary Table,
online only) shows that we were able to accurately capture
a transition period in the coding of type B dissection. As
alluded to previously, many of these limitations will be
addressed when our future work examines the reasons for
underlying changes in practice patterns and outcomes
with use of clinical data sets.CONCLUSIONS
Rates of type B dissection repair have increased over
time, which can be primarily attributed to the adoption of
TEVAR. Patients treated with TEVAR have more comor-
bidities than do those treated with open repair, but despite
this, perioperative mortality rates have improved dramati-
cally among all patients undergoing type B dissection repair.
The more prominent role of TEVAR appears to be justiﬁed,
although additional work needs to be performed to deﬁne
the patient population that will most beneﬁt from endovas-
cular treatment. Future efforts toward improving patientselection should speciﬁcally consider gender-based differ-
ences in open and endovascular outcomes.AUTHOR CONTRIBUTIONS
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Supplementary Table (online only). International
Classiﬁcation of Diseases, Ninth Revision (ICD-9)
procedural code use by year, 2000-2010
Year
OSR TEVAR
ICD-9 38.35 ICD-9 38.45 ICD-9 39.73 ICD-9 39.79
2000 1 842 0 11
2001 2 812 0 48
2002 4 881 0 51
2003 4 883 0 51
2004 2 863 0 66
2005 4 895 43 73
2006 5 869 218 7
2007 3 842 237 10
2008 1 843 261 10
2009 4 807 298 16
2010 1 870 302 19
OSR, Open surgical repair; TEVAR, thoracic endovascular aortic repair.
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